NORTH TEXAS (CBSDFW.COM) — A brand new research by the World Well being Group exhibits the COVID-19 therapy drug – referred to as remdesivir – doesn’t stop demise amongst sufferers.
A CBS 11 iTeam investigation from earlier this week took an in-depth have a look at remdesivir.
The iTeam discovered research have proven the drug can scale back the size of hospital stays in COVID-19 sufferers – often shortening it from 15 days to 11.
However thus far, research haven’t proven that remdesivir has a major impact on lowering demise.
Outcomes of the trial indicated that remdesivir and three different potential coronavirus therapy medication — hydroxychloroquine, lopinavir/ritonavir and interferon — “appeared to have little or no impact on 28-day mortality or the in-hospital course of COVID-19 amongst hospitalized sufferers.”
Gilead Sciences – the maker of remdesivir – disputes the most recent conclusion from WHO, saying that a large-scale trial they carried out discovered the drug does, in actual fact, have life-saving advantages.
Remdesivir is at present the one antiviral drug approved within the U.S. to deal with COVID-19.
The CBS 11 iTeam report particulars extra about remdesivir, including the controversy surrounding the price of the drug. Remdesivir prices greater than $three,000 per therapy for sufferers with non-public insurance coverage.